Statements (21)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:CEO |
gptkb:Anthony_Quinn
|
| gptkbp:developedBy |
gptkb:pegzilarginase
|
| gptkbp:focusesOn |
rare diseases
arginase deficiency enzyme therapeutics |
| gptkbp:foundedBy |
gptkb:Andrew_Ellington
gptkb:David_G._Lowe gptkb:Naveen_Singh gptkb:George_Georgiou gptkb:Scott_L._Donaldson |
| gptkbp:foundedYear |
2013
|
| gptkbp:headquartersLocation |
gptkb:Austin,_Texas,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Aeglea BioTherapeutics
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:listedOn |
gptkb:NASDAQ
|
| gptkbp:publiclyTraded |
yes
|
| gptkbp:stockSymbol |
gptkb:AGLE
|
| gptkbp:website |
https://www.aeglea.com/
|
| gptkbp:bfsParent |
gptkb:Nessan_Bermingham
|
| gptkbp:bfsLayer |
7
|